H1 Winners And Laggards In China's Sizzling Home-Grown IO market
Newcomers Chase Leaders
Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.
